We investigated the mechanism of interaction of individual L-type channel amino acid residues with dihydropyridines within a dihydropyridine-sensitive ␣1A subunit (␣1A DHP ). Mutation of individual residues in repeat III and expression in Xenopus oocytes revealed that Thr 1393 is not required for dihydropyridine interaction but that bulky side chains (tyrosine, phenylalanine) in this position sterically inhibit dihydropyridine coordination. In position 1397 a side chain carbonyl group was required for high antagonist sensitivity. Agonist function required the complete amide group of a glutamine residue. The membrane depolarization-dependent opening of voltagegated Ca 2ϩ channels effectively modulates Ca 2ϩ influx into electrically excitable cells. These channels represent key elements in Ca 2ϩ signaling, controlling neurotransmitter release, synaptic plasticity, muscle contraction, and pacemaker functions. So far selective nonpeptide Ca 2ϩ channel modulators have only been developed for L-type Ca 2ϩ channels which are expressed primarily in the cardiovascular system but also in neuronal and neuroendocrine cells (1, 2). Other Ca 2ϩ channel types, such as N, P, Q, and R-type Ca 2ϩ channels, play a prominent role for fast neurotransmitter release in neurons (1), but they are insensitive to L-type Ca 2ϩ channel modulators. 1,4-Dihydropyridines (DHPs), 1 such as isradipine or amlodipine, are very well characterized L-type Ca 2ϩ channel blockers ("antagonists") that are also used to treat cardiovascular diseases. In contrast, DHP Ca 2ϩ channel activators ("agonists,"
The membrane depolarization-dependent opening of voltagegated Ca 2ϩ channels effectively modulates Ca 2ϩ influx into electrically excitable cells. These channels represent key elements in Ca 2ϩ signaling, controlling neurotransmitter release, synaptic plasticity, muscle contraction, and pacemaker functions. So far selective nonpeptide Ca 2ϩ channel modulators have only been developed for L-type Ca 2ϩ channels which are expressed primarily in the cardiovascular system but also in neuronal and neuroendocrine cells (1, 2) . Other Ca 2ϩ channel types, such as N, P, Q, and R-type Ca 2ϩ channels, play a prominent role for fast neurotransmitter release in neurons (1), but they are insensitive to L-type Ca 2ϩ channel modulators. 1,4-Dihydropyridines (DHPs), 1 such as isradipine or amlodipine, are very well characterized L-type Ca 2ϩ channel blockers ("antagonists") that are also used to treat cardiovascular diseases. In contrast, DHP Ca 2ϩ channel activators ("agonists,"
e.g. BayK8644) stimulate Ca 2ϩ currents through L-type channels. DHPs do not modulate ion currents through, e.g. P-or Q-type channels.
This difference in DHP sensitivity is the result of different ␣1 subunit isoforms which, together with accessory subunits such as ␣2-␦ and ␤, form the Ca 2ϩ channel complexes. L-type Ca 2ϩ channels are formed, e.g. by DHP-sensitive ␣1C or ␣1S subunits, whereas P-and Q-type Ca 2ϩ channels contain DHPinsensitive ␣1A subunits.
Individual amino acid residues that form the DHP binding pocket in L-type ␣1 subunits have recently been identified (for review, see Refs. [3] [4] [5] . Most interestingly, some but not all of these residues are conserved in non-DHP-sensitive subunits, such as ␣1A and ␣1E. These subunits are rendered fully DHP agonist-and antagonist-sensitive after introduction of the remaining nonconserved L-type residues forming the binding pocket (yielding, e.g. DHP-sensitive ␣1A subunits, ␣1A DHP (6, 7)).
Although site-directed mutagenesis has been used to identify residues important for DHP interaction, the exact role of some of these residues in antagonist and agonist interaction has not been completely studied. In addition, for some of these L-type residues it is still unclear if their introduction into ␣1A creates additional interaction sites for the DHP molecule or removes an inhibitory effect of the corresponding ␣1A residue. A more detailed insight into the molecular mechanisms of DHP binding to its recombinant drug binding domain in ␣1A DHP could provide important structural information for developing small molecules with affinity for ␣1A subunits. Such drugs could be useful therapeutics for the treatment of ␣1A-associated disorders such as migraine (8) .
To address this question we used site-directed mutagenesis to study further the mechanism of DHP interaction with L-type residues in repeat III of a DHP-sensitive ␣1A subunit (␣1A DHP ). By carrying out these studies within the ␣1A background our results can be applied to future studies aimed at the development of ␣1A-selective Ca 2ϩ channel modulators.
EXPERIMENTAL PROCEDURES
Construction of Mutant ␣1 cDNAs-The construction of ␣1A DHP and M1512V (␣1A DHPi ) was described previously (6) . Mutations were introduced into ␣1A DHP cDNA containing silent restriction sites (indicated by asterisks) generated by polymerase chain reaction (PCR) in previous cloning steps (9) . Mutant ␣ 1 cDNAs were created by PCR using the "gene SOEing" technique (10) employing proofreading Pfu polymerase (Stratagene).
Mutations of Thr 1393 and Gln 1397 (␣1A numbering (11); corresponding to positions 1039 and 1043 in ␣1C-II, respectively (12)) were introduced by PCR using appropriately mutated SOE-PCR primers into a SfiI-SalI* cassette (nucleotides 4297-4744, ␣1A numbering) of an XhoI-ClaI* fragment (nucleotides 1689 -4925, domains II and III) of ␣1A DHP subcloned into pBluescript SK ϩ (Stratagene). The mutations were reintroduced through an NheI-ClaI* fragment (nucleotides 3543-4925, domain III) into ␣1A DHP in PNKS 2 (provided by O. Pongs, ZFMNB, Hamburg, Germany), thus yielding the following ␣1A DHP mutants: T1393A, T1393Y, T1393F, T1393S, Q1397A, Q1397M, Q1397E, * This work was supported by Austrian Science Fund Grants P12641 and P14820 (to J. S.) and P12689 (to H. G.), by the Ö sterreichische Nationalbank, the Dr. Legerlotz Foundation, and European Community Research Training Network Grant HPRN-CT-2000 00082 (to J. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed. Krieg and Melton (13) . ␣1 cRNA was coinjected with ␤1a (14) and ␣2␦ (15) subunit cRNAs into stage V-VI oocytes from X. laevis.
Electrophysiological Measurements-1-6 days after cRNA injection inward barium currents (I Ba ) through voltage-gated Ca 2ϩ channels were measured at room temperature using the two-microelectrode voltage-clamp technique as described previously (9) . To quantifiy endogenous I Ba X. laevis oocytes injected only with ␤1a and ␣2␦ were analyzed in parallel. Only oocytes expressing peak I Ba through recombinant Ca 2ϩ channels at least three times as high (usually Ͼ100 nA) as the highest endogenous currents were included into analysis. Data analysis and acquisition were performed by using the pClamp software package (version 6.0, Axon Instruments). Leakage correction was performed by adjusting the current traces by a factor calculated from the difference between the leak at Ϫ80 mV and Ϫ90 mV, respectively.
The extracellular solution contained 40 mM Ba(OH) 2 , 50 mM NaOH, 2 mM CsOH, and 5 mM HEPES (pH adjusted to 7.4 with methanesulfonic acid). The voltage recording and current-injecting microelectrodes were filled with 2.8 M CsCl, 0.2 M CsOH, 10 mM HEPES, and 10 mM EGTA (adjusted to pH 7.4 with HCl) and had resistances of 0.7-6 megohms.
Modulation of peak I Ba was measured from the indicated standard holding potentials to a test pulse corresponding to the peak potential (I Ba block by DHP antagonists) or 10 mV positive to the peak potential of the current-voltage relations (I Ba stimulation by DHP agonist and FPL64176, respectively). Standard pulse frequency was 0.017 or 0.034 Hz to assess channel modulation. Isradipine was employed at a concentration (10 M) causing near complete channel block in oocytes at negative holding potentials (6) .
The time course of peak current inhibition by isradipine was estimated by fitting the peak currents of successive episodes to a monoexponential function (I Ba ϭ A*exp(Ϫt/) ϩ C).
Because of slow recovery from inactivation, steady-state inactivation was quantified from the decline of peak I Ba after switching from a holding potential of Ϫ120 mV to more positive holding potentials allowing equilibrium I Ba to be reached. For mutant V1516A, which showed relatively little inactivation at Ϫ80 mV, Ϫ100 mV was used as reference potential for the resting state.
Reagents-(Ϯ)-Isradipine (PN200-110) was from Sandoz AG (Basel, Switzerland), (Ϯ)-BayK8644 was from Bayer AG (Wuppertal, Germany), and FPL64176 was from Fisons Pharmaceuticals (Leicestershire, U. K.). Drug-containing solutions were freshly prepared from 10 mM stock solutions (in dimethyl sulfoxide) and applied at the same flow rate as control solution.
Statistics-Data are given as the mean Ϯ S.D. Statistical significance was calculated using the unpaired Student's t test, employing Origin R (Microcal, version 6.0).
RESULTS
We and others have shown recently that ␣1A (␣1A DHP , Fig.  1A ) and ␣1E subunits become highly DHP-sensitive by mutation of 8 -9 amino acids to residues present in L-type ␣1 subunits (6, 7, 16) . In this study we used ␣1A DHP as a suitable model to study further the mechanism by which amino acid residues in transmembrane segments IIIS5 and IIIS6 participate in DHP interaction. The ␣1A structural background should allow application of the results for ␣1A drug development. 
Role of Thr 1393 in Transmembrane Helix IIIS5-Previous
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corresponding ␣1A residues (T1393Y, Q1397M) substantially decreased DHP sensitivity. It is unclear if this is because of a steric interference introduced by the corresponding tyrosine or methionine side chain, respectively, or the result of the removal of the appropriate pharmacophores. To address this question we replaced Thr 1393 or Gln 1397 in ␣1A DHP by a series of other residues and tested the consequences of these mutations for modulation of I Ba by the DHP Ca 2ϩ channel blocker isradipine and activator BayK8644 after expression in Xenopus oocytes. In agreement with previous results, 10 M isradipine inhibited 72.1 Ϯ 6.9% (n ϭ 4, Fig. 1C ) of I Ba through ␣1A DHP elicited from a holding potential of Ϫ80 mV. 10 M BayK8644 stimulated I Ba by 4.3 Ϯ 1.2-fold (n ϭ 4). Sensitivity was abolished after mutation of Thr 1393 to tyrosine (mutant T1393Y: 4 Ϯ 8.3% inhibition, n ϭ 5; 1.4 Ϯ 0.7-fold stimulation, n ϭ 7). T1393Y was also insensitive to stimulation by the non-DHP agonist FPL64176 (1.04 Ϯ 0.1 fold stimulation, n ϭ 3). Fig. 1C shows that reduction of the side chain size by mutation from threonine to serine (mutant T1393S: 59.2 Ϯ 16.3% inhibition, n ϭ 3; 3.6 Ϯ 0.4-fold stimulation, n ϭ 5; p Ͼ 0.05) or alanine (mutant T1393A: 59.5 Ϯ 10.3% inhibition, n ϭ 5; 5.6 Ϯ 2.8-fold stimulation, n ϭ 4, p Ͼ 0.05) not only preserved full DHP antagonist sensitivity but also supported stimulation by BayK8644. These results show that the side chain of Thr 1393 is not essential for DHP modulation. Instead, the bulky hydroxyphenyl moiety of tyrosine must prevent DHP interaction (19) .
To determine whether DHP antagonist sensitivity was affected by membrane voltage, inhibition by isradipine was measured also at Ϫ100 mV holding potential at which a much smaller fraction of channels underwent steady-state inactivation than at Ϫ80 mV ( Table I) . As for ␣1A DHP ( Fig. 2; 20) , DHP sensitivity was not affected by membrane voltage in T1393A (Ϫ100 mV: 62.1 Ϯ 10, 5% inhibition, n ϭ 4) and T1393Y ( Fig.  2;) . No significant antagonist sensitivity of T1393Y was recovered at holding potentials causing 70% steady-state inactivation (12.0 Ϯ 13.2%, n ϭ 3; Fig. 2 ). Steady-state inactivation properties of mutant T1393Y were similar to ␣1A DHP (Table I) . This rules out decreased antagonist sensitivity of T1393Y being caused by changes in channel inactivation properties.
Next we investigated whether the hydroxyl group of the tyrosine side chain contributes to the reduction of DHP sensitivity in T1393Y by creating mutant T1393F. As illustrated in Fig. 2 , the isradipine sensitivity of peak I Ba through T1393F was reduced dramatically at Ϫ100 mV holding potential (8.8 Ϯ 5.0% inhibition, n ϭ 3), and stimulation by BayK8644 was negligible (1.34 Ϯ 0.28-fold stimulation, n ϭ 3, Fig. 1 ). However, isradipine increased I Ba decay during depolarization causing 42 Ϯ 20% (n ϭ 3) inhibition at the end of the 350-ms test pulse ( Fig. 2A) . This indicated that the drug still interacts with depolarized channels. The increase in I Ba decay may be caused by preferential interaction with or promotion of inactivated channel states (20) and prompted us to study DHP block at more depolarized holding potentials. Unlike T1393Y, DHP antagonist sensitivity of T1393F increased substantially at more positive holding potentials, and inhibition of peak I Ba was recovered completely at potentials causing 70% steady-state inactivation (Fig. 2) . Interestingly, development of block was slowed compared with ␣1A DHP (T1393F: ϭ 4.51 Ϯ 1.38 min, n ϭ 6; ␣1A DHP : ϭ 2.28 Ϯ 0.26 min, n ϭ 4, p Ͻ 0.05).
No evidence for a similar voltage-dependent action was found for BayK8644 (Fig. 1C) . Taken together our experiments show that the tyrosine's phenyl ring alone is sufficient to decrease ␣1A DHP antagonist sensitivity at negative potentials but , and T1393F to inhibition by 10 M isradipine at different holding potentials. One typical recording out of at least three experiments is shown. I Ba was elicited by depolarizations to potentials corresponding to the peak of the current-voltage relations. ISR, isradipine; Co, control. 70% channel inactivation was achieved at the following holding potentials: ␣1A DHP , Ϫ65 mV; T1393Y, Ϫ61 mV; T1393F, Ϫ70 mV. 50% channel inactivation was achieved at Ϫ74 mV (T1393F). Cells: ␣1A DHP : Ϫ120 mV, e0724029; 70% inactivation, e0309024; T1393Y: Ϫ100 mV, e9317029; 70% inactivation, e0218051; T1393F: Ϫ100 mV, e9818020; Ϫ80 mV, e9506033; 50% inactivation, e0309036; 70% inactivation, e0309031. B, inhibition of peak I Ba by 10 M isradipine through ␣1A DHP and the indicated mutants at different holding potentials. 70% channel inactivation was achieved at the following holding potentials: ␣1A DHP , Ϫ65-74 mV; T1393Y, Ϫ61-70 mV; T1393F, Ϫ70 -77 mV; V1516A, Ϫ50 -55 mV. 50% channel inactivation was achieved at the following holding potentials: T1393F, Ϫ74 -80 mV; V1516A, Ϫ50 -62 mV. Data are presented as the mean Ϯ S.D. from the indicated number of experiments; a statistically significant difference from ␣1A DHP at the same holding potential (or at Ϫ80 mV) is indicated: *, p Ͻ 0.05; **, p Ͻ 0.01.
that the additional hydroxyl group is required to maintain this effect at more positive voltages.
Role of Gln 1397 in IIIS5-Previous experiments have shown that mutation of IIIS5 Gln
1397 to the corresponding methionine (17, 18) reduces DHP sensitivity. This was also observed after introduction of this mutation (Q1393M) into ␣1A DHP (Fig. 1C) . Antagonist sensitivity was decreased, and simulation by the agonists FPL64176 (0.95 Ϯ 0.13-fold stimulation, n ϭ 3) and BayK8644 (Fig. 1C) was abolished. In contrast to Thr 1393 , introduction of an alanine, resulting in mutant Q1397A, did not support full DHP antagonist (29.6 Ϯ 13.5% inhibition, n ϭ 7) and agonist (1.4 Ϯ 0.15-fold stimulation, n ϭ 5) sensitivity (Fig.  1C) . This indicates that the side chain of Gln 1397 participates directly in DHP binding. Replacement of glutamine by asparagine, which shortens the side chain by one methylene group, conferred full antagonist sensitivity (68.8 Ϯ 9.8%, n ϭ 5, p Ͼ 0.05) but significantly reduced stimulation by the agonist (1.8 Ϯ 0.66-fold, n ϭ 5). A similar finding was obtained for mutant Q1397E (63.5 Ϯ 15% inhibition, n ϭ 5; 1.8 Ϯ 0.36-fold stimulation, n ϭ 4) and Q1397D (17) in which the side chain NH 2 groups are replaced by OH groups. Taken together these results confirm our previous hypothesis that the carbonyl group (present in the amide and carboxyl side chains) in position 1397 is sufficient for DHP antagonist sensitivity, whereas full agonist action requires the complete amide moiety. Our data show that the latter must even be located in an appropriate distance from the IIIS5 backbone because only glutamine but not asparagine supports full activity. 1507 have not yet been determined within the ␣1A DHP background. As shown in Fig. 3B , mutation of these residues to alanine did not decrease antagonist sensitivity (Ϫ80 mV). This is consistent with previous results obtained with mutated ␣1C subunits, in which only 2.5-5-fold lower affinities at Ϫ80 mV were reported for these single mutations in functional experiments (22) . As in ␣1C (22), mutation Y1503A, but not I1504A and I1507A, abolished agonist stimulation of peak current (Fig. 3B) . The activating effect of BayK8644 was converted into an inhibitory one, evident as inhibition of 42 Ϯ 8.4% (n ϭ 3) of I Ba at the end of the 350-ms test pulse (Fig. 3C ). This demonstrates that the mutation does not block DHP interaction with the channel but prevents the agonist from stabilizing open channel conformations. Because BayK8644 is employed as the racemic mixture of an agonist ((Ϫ)-enantiomer) and a weak antagonist ((ϩ)-enantiomer), I Ba inhibition most likely reflects channel block by the antagonistic enantiomer in the absence of stimulation by the agonist. This is supported further by the finding of the complete lack of I Ba modulation by the optically pure agonist FPL64176 (0.97 Ϯ 0.12-fold stimulation, n ϭ 3).
Role of IIIS6 Residues-Previous
To address the question of whether DHP sensitivity is still maintained after back-mutation of L-type residues in positions 1504 and 1507 to the corresponding ␣1A phenylalanines, we constructed mutants I1504F and I1507F. Both mutants showed only minor and nonsignificant decreases in isradipine inhibition compared with ␣1A DHP . This demonstrates that the DHP sensitivity of ␣1A can be achieved by introduction of an even lower number of L-type residues into ␣1A DHP than described previously. Both mutants were efficiently stimulated by 10 M BayK8644. In the case of I1507F, stimulation was even more pronounced than for ␣1A DHP (15.6 Ϯ 7.6-fold, n ϭ 7). Such an enhancement was also found for stimulation by FPL64176, although not on the level of statistical significance (I1507F: 4.1 Ϯ 
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1.16-fold, n ϭ 4, Fig. 3C ; ␣ 1A-DHP : 2.8 Ϯ 0.84-fold, n ϭ 3 (6)).
We also analyzed the requirement of the Met 1512 side chain for agonist action. In agreement with earlier studies (21) mutation M1512A reduced isradipine sensitivity (Fig. 3B) , suggesting that the Met 1512 side chain interacts directly with the DHP antagonist. This side chain preferentially mediated antagonist effects because stimulation by BayK8644 was not affected by the mutation (5.5 Ϯ 2.6-fold stimulation, n ϭ 6). This is in contrast to our previous observation in which substitution of this residue by a valine reduced both agonist and antagonist sensitivity (Fig. 3B (6) ).
Other residues in IIIS6 which may affect drug modulation by DHPs are Pro 1508 and Val
1516
. In position 1508 both alanine and proline support high affinity DHP antagonist interaction in ␣1C (23) and ␣1A DHP (Fig. 3B) . However, mutation of Pro 1508 to alanine may cause mutation-induced conformational changes of the IIIS6 helix (24) which could affect modulation by agonists. This possibility has not yet been investigated. We found no evidence for such an effect in P1508A (Fig. 3B) . Val 1516 , which is conserved in L-and non-L-type Ca 2ϩ channel ␣1 subunits, was recently found to contribute to Ca 2ϩ channel block by phenylalkylamines (25) and (ϩ)-cis-diltiazem (26), but its contribution to DHP sensitivity is unknown. Figs. 2 and 3 illustrate that mutation V1516A decreased stimulation by BayK8644 and inhibition by isradipine at a Ϫ80 mV holding potential. As for T1393F, V1516A increased I Ba decay during the test pulse. At Ϫ80 mV peak I Ba was reduced by 21 Ϯ 12% (n ϭ 5), but I Ba at the end of the 350-ms test pulse was reduced by 55 Ϯ 15% (n ϭ 5). This mutation also introduced voltage dependence for isradipine block, as decreased DHP sensitivity was not observed at holding potentials where 70% of the channels were inactivated (Fig. 2) . In contrast to T1393F, no slowing of isradipine block development was evident ( ϭ 1.53 Ϯ 0.96 min, n ϭ 3).
DISCUSSION
We have studied the contribution of residues previously found to mediate sensitivity of L-type Ca 2ϩ channel ␣1 subunits to DHP Ca 2ϩ channel blockers and activators. Our data (summarized in Fig. 4 ) provide further structural insight into the differential affinity of ␣1A and L-type ␣1 subunits for DHP Ca 2ϩ channel modulators. Decreased DHP sensitivity after the introduction of bulky tyrosine or phenylalanine residues into position 1393 of ␣1A (T1393Y, T1393F) is not caused by the removal of a critical binding contact. Instead, the bulky side chains sterically prevent high affinity DHP interaction. In T1393F, i.e. in the absence of the tyrosine hydroxyl group, obstruction of DHP antagonist interaction is only found for resting channels but is nearly absent when channels are inactivated. It is tempting to speculate that the hydroxyl function stabilizes a certain orientation of the tyrosine side chain which interferes with DHP antagonist coordination independent of channel conformation. This may be accomplished, e.g. by forming a hydrogen bond with other residues. From a working model of the DHP binding domain (19) based on the three-dimensional coordinates of the kcsA potassium channel (24) the carbonyl oxygen of the IIIS6 Met 1511 would be the most likely candidate for such hydrogen bonding (not shown). Removal of the hydroxyl group (in mutant T1393F) still prevents high DHP antagonist sensitivity of resting channels but restores sensitivity when the channels inactivate. We propose that hydrogen bonding does not occur without the hydroxyl group, providing the phenyl group with more rotational flexibility such that DHP antagonist binding to inactivated states is possible. This flexibility may delay, but not prevent, DHP association to the channel. Such a model can explain the observed slower onset of DHP block of I Ba through T1393F compared with ␣1A DHP .
We present evidence that, in contrast to Thr 1393 , the Glu 1397 side chain is involved directly in DHP binding. Maximal DHP antagonist sensitivity critically depends on the presence of a side chain carbonyl group, a potential hydrogen bond acceptor, whereas DHP agonist action requires an intact amide function spaced at a defined distance (glutamine amide) from the IIIS5 protein backbone. Introduction of nine L-type channel amino acids into ␣1A renders the resulting DHP-sensitive construct (␣1A DHP ) highly sensitive to DHPs. Although ␣1A DHP retains most of the hallmarks of DHP interaction with L-type Ca 2ϩ channel ␣1A subunits (such as high affinity, stereoselectivity, and allosteric modulation by non-DHP Ca 2ϩ antagonists (19) ), the typical voltage dependence of DHP block is absent (20) . This has also been described previously for a DHP-sensitive ␣1E subunit construct (27) . We show that the change of only a single amino acid residue can introduce considerable voltage dependence of the DHP block into ␣1A DHP . This is an important observation because the molecular mechanism for voltage-dependent Ca 2ϩ channel block by DHPs is not well understood. Our experiments clearly demonstrate that first, alterations of single amino acid side chains affect voltage-dependent DHP block. In previous studies the voltage dependence of ␣1C subunits has been associated with sequence divergence of multiple residues within larger sequence stretches (comprising transmembrane segment IS6 (27, 28) ). Second, we found that single mutations within two distinct but adjacent transmembrane segments of the DHP binding domain can modify the voltage dependence of DHP inhibition of ␣1A DHP by apparently different mechanisms. The addition of a bulky phenylalanine in position 1393 mainly decreases DHP antagonist sensitivity for resting channels. This steric hindrance decreases when the channel assumes the inactivated conformation (see above). A different mechanism seems to apply for mutation V1516A. In this case, DHP sensitivity also decreases mainly for resting channels after removal of the valine side chain by mutation to alanine. This suggests that the valine side chain is essential for DHP action in the resting channel conformation but is not important once the channel inactivates. The relative contribution of individual residues for DHP binding must therefore change upon depolarization. We cannot distinguish whether the Val 1516 side chain interacts directly with the DHP molecule in the resting state or contributes indirectly to a hydrophobic stabilization of the binding domain which is disrupted by its mutation to alanine. Taken together, our experiments identify two basic mechanisms that explain voltage-dependent changes in DHP sensitivity, at least in ␣1A DHP Ca 2ϩ channels: gating-induced molecular rearrangements within the DHP binding domain can alter DHP antagonist affinity either by changing the extent of steric hindrance by a particular residue (such as in T1393F) or by providing (or stabilizing) suitable attachment sites for the drug (such as in V1516A).
Our results contribute important information for the development of P/Q-type Ca 2ϩ channel-selective modulators. DHP derivatives would represent ideal lead compounds for the development of ␣1A Ca 2ϩ channel modulators. Investigation of the DHP binding domain within the ␣1A sequence background of ␣1A DHP not only reveals information about the molecular mechanism of DHP interaction with L-type Ca 2ϩ channel ␣1 subunits in general, but also provides structural hints for novel DHP analogs that could possess considerable affinity for ␣1A subunits and therefore represent lead compounds for further drug development.
We found that in the ␣1A sequence environment the two L-type isoleucine residues in IIIS6 (Ile 1504 , Ile 1507 ) are not important for DHP interaction and can be replaced by the respective ␣1A phenylalanines. Therefore transfer of high DHP sensitivity to ␣1A requires the introduction of even less than 9 L-type residues as reported for ␣1A DHP (6, 7) . From one of our previous studies with ␣1A chimeras (9) it is evident that DHP antagonist sensitivity only very weakly depends on the four L-type residues in repeat IV (Fig. 1A) . Therefore, DHP interaction with the remaining three L-type channel amino acid residues in IIIS5 and IIIS6 (Thr 1393 , Gln 1397 , and Met 1512 ) is crucial for DHP sensitivity of ␣1A DHP . The strongest structural determinant abolishing DHP sensitivity in ␣1A is the tyrosine in position Thr 1393 which, according to our data, sterically prevents DHP binding. In contrast, there is no evidence for such an effect for ␣1A residues introduced into positions 1397 and 1512. Instead, these fail to provide suitable attachment sites for the DHP molecule thus leading to a measurable but limited sensitivity decrease. It is therefore likely that drug molecules (e.g. DHP derivatives) that escape the steric hindrance of Tyr 1393 and do not depend on binding interaction with Met 1512 and Gln 1397 must have considerable Ca 2ϩ channel blocking effects for ␣1A subunits. Smaller and more hydrophobic compounds may fulfill these requirements.
Together with the results from earlier studies (9, 17, 18, 22, 29) our data show that the structural requirements for effective stimulation by DHP agonists of I Ba through ␣1A DHP are more complex than for antagonists. This is based on the observation that introduction of the ␣1A sequence into several L-type positions of ␣1A DHP in repeats III (1393, 1397, 1512) and IVS6 (9) results in a complete loss of agonist sensitivity to 10 M concentrations of BayK8644 and FPL64176. Most of these mutations and mutation Y1503A illustrate that DHP agonist effects can be removed completely in mutants still displaying antagonist sensitivity (e.g. Q1397M, Y1503A, M1512V; Fig. 3) . In radioligand binding studies DHP agonists and antagonists bind to their binding domain in an apparently competitive manner. It is therefore likely that such mutations still allow DHP agonist binding to the channel but are unable to stabilize or prevent stabilization of open channel conformations by the bound agonist. A similar conclusion was reached after mutation of a pore-loop serine (position 1466 in ␣1A DHP ), which prevents agonist effects but appears still to mediate antagonist sensitivity (5) .
In summary, our data provide important insight into DHP interaction with their binding domain within the structural background of ␣1A. This molecular information provides clues for the development of ␣1A-selective Ca 2ϩ channel blockers.
